ArticleJournal for immunotherapy of cancer2023
Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses.
Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Enhancing immunogenic cell death by targeting the GPX4-ZP3 immune checkpoint.Oncoimmunology · 2026Article
- Unveiling the genomes and secondary metabolomes ofFrontiers in microbiology · 2026Article
- Mining Actinomycetes' Metabolomes and Genomes for Anti-Phytophthora infestans Compounds.Microbial biotechnology · 2025Article
- Chondroitin sulfate nanoparticles based on co-delivery dual drug induced ferroptosis in lung cancer cells by disrupting mitochondrial oxidative homeostasis.Materials today. Bio · 2025Article
- Astemizole Exacerbates 5-Fluorouracil-Triggered Cardiotoxicity by Enhancing Ptgs2.Cardiovascular toxicology · 2025Article
- Comparison of fecal microbiota and metabolites in diarrheal piglets pre-and post-weaning.Frontiers in veterinary science · 2025Article
- Targeting immunogenic cell stress and death for cancer therapy.Nature reviews. Drug discovery · 2024Review
- CD8Frontiers in immunology · 2024Review
- Elimination of cDC1 cells by regulatory T cells jeopardizes cancer immunotherapy.Oncoimmunology · 2024Article
- The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation.Cell death and differentiation · 2023Review
- Conventional type 1 dendritic cells (cDC1) in cancer immunity.Biology direct · 2023Review
- Histamine antagonists promote cancer immunosurveillance.Oncoimmunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundMost immunotherapies approved for clinical use rely on the use of recombinant proteins and cell-based approaches, rendering their manufacturing expensive and logistics onerous. The identification of novel small molecule immunotherapeutic agents might overcome such limitations.
methodFor immunopharmacological screening campaigns, we built an artificial miniature immune system in which dendritic cells (DCs) derived from immature precursors present MHC (major histocompatibility complex) class I-restricted antigen to a T-cell hybridoma that then secretes interleukin-2 (IL-2).
resultsThe screening of three drug libraries relevant to known signaling pathways, FDA (Food and Drug Administration)-approved drugs and neuroendocrine factors yielded two major hits, astemizole and ikarugamycin. Mechanistically, ikarugamycin turned out to act on DCs to inhibit hexokinase 2, hence stimulating their antigen presenting potential. In contrast, astemizole acts as a histamine H1 receptor (H1R1) antagonist to activate T cells in a non-specific, DC-independent fashion. Astemizole induced the production of IL-2 and interferon-γ (IFN-γ) by CD4
conclusionsThese findings underscore the potential utility of this screening system for the identification of immunostimulatory drugs with anticancer effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.